NPPA seeks clarification on Gilead's drug pricing plea

National Pharmaceutical Pricing Authority has sought clarifications
from the company. Gilead had sought exemption from price control for
its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a
major chunk of Rs 140-crore market for chronic Hepatitis B in India.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms

Comments

Popular posts from this blog

TIGS-CI Biological Sciences Research Assistant Recruitment, Apply Online

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission

Biotecnika Times – Newsletter 25.01.2021 – CSIR Notice, CSIR-CCMB & ILS Hiring, FSSAI Funded